In the present study, we determined the radiosensitising potential of rucaparib and olaparib, two PARP-1 inhibitors currently undergoing phase II/III clinical investigation, in combination with external beam X-radiation or the neuroblastoma-targeting radiopharmaceutical 131I-MIBG. The gene discussed is PARP1; the disease is neuroblastoma.